• Like
RI: Oral Small Molecules for RA Face High Price-Sensitivity Hurdles
Upcoming SlideShare
Loading in...5

Thanks for flagging this SlideShare!

Oops! An error has occurred.

RI: Oral Small Molecules for RA Face High Price-Sensitivity Hurdles



  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads


Total Views
On SlideShare
From Embeds
Number of Embeds



Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

    No notes for slide


  • 1. Oral Small Molecules for RA Face High Price-Sensitivity HurdlesMADISON, N.J., March 20, 2012 – Reimbursement Intelligence, the New Jersey-based marketresearch firm helping biopharma, medical device and diagnostics firms succeed in managedmarkets, announced the launch of the 2012 Rheumatology Insight Service, a subscription-basedmarket research based on parallel surveys of 100 rheumatologists and 50 payers, which will becontinuously updated throughout 2012.The study, quoted in this morning’s Pharmalot, “Yielded some important customer insights,”said Rhonda Greenapple, CEO of RI. “One key finding is that the new, oral small molecules forRA are not necessarily a slam-dunk for either payers or rheumatologists.”Greenapple continued, “There was no clear, natural positioning for these agents in RA therapy.Payers and rheumatologists considered them part of the same ‘class’ as RA biologics, and thatwhere they would be used was highly dependent on cost. Their views varied substantially basedon different pricing scenarios.”“We think the message for manufacturers is clear,” said Greenapple. “If the manufacturers ofnovel agents for RA – including the oral small molecules – don’t clearly position these productsin customers’ minds, customers, especially payers, will do it for them.”Adoption of these agents will be further challenged by the trend toward shifting of specialtypharmaceuticals to a Tier 4 with higher out-of-pocket costs. Said Greenapple, “Somerheumatologists told us they thought patients will start asking about the new oral small moleculesas soon as they’re available. The big question is whether they’re going to be willing to payseveral hundred dollars per month for these medications. Manufacturers have to focus onmessaging for three different customer segments – rheumatologists, payers, and patients. It willtake a compelling patient value proposition to motivate patients to start and stay on these newmedications.”About the Rheumatology Insight ServiceThe Rheumatology Insight Service is the first of a new series of category-specificReimbursement Insight subscription services available only from Reimbursement Intelligence.The core component of the Rheumatology Insight Service is the 2012 RheumatologyReimbursement Report, featuring more than 50 pages of carefully crafted findings, with thought-provoking commentary from RI’s panel of RA category experts. Subscribers to the survey willreceive three quarterly updates, periodic event-driven updates, and access to customized sub-analyses of specific customers segments, based on subscriber-requested criteria.For additional information about the 2012 Rheumatology Insight Service and for all otherinquiries, please click here: 2012 Rheumatology Insight Service 2 Shunpike Road, 3rd Floor Madison, NJ 07940 p: 973.805.2300 f: 973.377.7930